Following on from information provided to NICE by the company, the appraisal of Melanoma (advanced and metastatic) - temozolomide was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company, the appraisal of Melanoma (advanced and metastatic) - temozolomide was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 January 2018 | In progress. In progress |
| 07 November 2017 - 06 December 2017 | Review proposal consultation |
For further information on our processes and methods, please see our CHTE processes and methods manual